Atrium Therapeutics (RNA) investor relations material

Executive summary

• Q3 collaboration revenue was $15.321M, including a $15.0M BMS milestone; net loss was $4.266M.

• First patient dosed in the ATR 1072 Corventis Phase 1/2 trial in October; initial proof-of-concept data are expected in 2H 2027.

• Pipeline includes ATR 1086 for PLN cardiomyopathy and two research-stage rare-cardiomyopathy programs; next development candidate expected to be selected in 2027.

Financial highlights

• Q3 2026 revenue was $15.321M versus $12.339M; operating expenses were $21.950M versus $12.552M.

• Nine-month revenue was $37.960M versus $17.759M; operating expenses were $84.487M versus $38.288M, and net loss was $41.085M versus $20.365M.

• Q3 R&D and G&A expenses were $13.8M and $8.2M; increases reflected ATR 1086 manufacturing and IND-enabling work, personnel, professional fees and lease costs.

• Nine-month R&D and G&A expenses were $45.8M and $38.7M; increases included an executive transition bonus and accelerated stock-based compensation vesting.

Outlook and guidance

• ATR 1086 IND filing and selection of the next development candidate are expected in 2027; initial ATR 1072 proof-of-concept data are expected in 2H 2027.

• Pro forma cash of $293.6M, including the BMS milestone and October private placement proceeds, is expected to fund operations through 2028.

• Existing cash, cash equivalents and short-term investments are expected to fund operations for at least 12 months from the filing date; R&D and G&A expenses are expected to rise as programs and infrastructure expand.